Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrECADD in HIV-Positive Advanced Classical Hodgkin Lymphoma
NCT06919679Phase 2Not yet recruiting
- Sponsor
- University of Cologne
- Start
- Aug 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Progression Free Survival at 1 year. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06919679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919679.